Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who received 2 mRNA vaccine doses. We found that 46% of HM patients did not produce antibodies and were...

Descripción completa

Detalles Bibliográficos
Autores principales: Agha, Mounzer, Blake, Maggie, Chilleo, Charles, Wells, Alan, Haidar, Ghady
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043479/
https://www.ncbi.nlm.nih.gov/pubmed/33851182
http://dx.doi.org/10.1101/2021.04.06.21254949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043479/
https://www.ncbi.nlm.nih.gov/pubmed/33851182
http://dx.doi.org/10.1101/2021.04.06.21254949

Ejemplares similares